Marker Therapeutics (MRKR) Receivables - Other (2013 - 2026)
Marker Therapeutics (MRKR) posted quarterly Receivables - Other of $1.4 million for Q1 2026, down 43.98% year-over-year from $2.5 million in Q1 2025, and up 2631.71% quarter-over-quarter from $50419.0 in Q4 2025.
Marker Therapeutics (MRKR) Receivables - Other (2013 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Receivables - Other for 10 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other fell 43.98% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (down 43.98% YoY), while the FY2025 annual figure was $1.4 million, down 41.65% from the prior year.
- Receivables - Other advanced to $1.4 million in Q1 2026 per MRKR's latest filing, from $50419.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $2.5 million in Q2 2024 and bottomed at $2185.0 in Q1 2022.
- Historically, Receivables - Other has averaged $1.4 million across 5 years, with a median of $1.7 million in 2025.
- On a YoY basis, Receivables - Other climbed as much as 1013403.8% in 2022 and fell as far as 99.78% in 2022.
- Marker Therapeutics' Receivables - Other stood at $2.4 million in 2022, then plunged by 57.21% to $1.0 million in 2023, then soared by 128.32% to $2.3 million in 2024, then sank by 97.85% to $50419.0 in 2025, then soared by 2631.71% to $1.4 million in 2026.
- Business Quant data shows MRKR's Receivables - Other at $1.4 million in Q1 2026, $50419.0 in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - |
| 10 | Marker Therapeutics | 26.07 Mn | 14.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.38 Mn |
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | 50,419.00 |
| Dec 31, 2025 | 50,419.00 |
| Sep 30, 2025 | 1.67 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 2.46 Mn |
| Mar 31, 2025 | 2.46 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 744,410.00 |
| Sep 30, 2024 | 744,410.00 |
| Jun 30, 2024 | 2.49 Mn |
| Jun 30, 2024 | 2.49 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |